A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol
Main Authors: | Ma, Xiao-Wei, Guo, Xiao-Hui, Xiao, Xin-Hua, Guo, Li-Xin, Lv, Xiao-Feng, Li, Quan-Min, Gao, Yan |
---|---|
Format: | Online |
Language: | English |
Published: |
Science Press
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470020/ |
Similar Items
-
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits
by: Wang, Yanli, et al.
Published: (2015) -
Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits
by: Münch, Götz, et al.
Published: (2012) -
Add-On Effect of Probucol in Atherosclerotic, Cholesterol-Fed Rabbits Treated with Atorvastatin
by: Keyamura, Yuka, et al.
Published: (2014) -
Mechanisms underlying probucol-induced hERG-channel deficiency
by: Shi, Yuan-Qi, et al.
Published: (2015) -
Arteriosclerosis
Published: (1925)